Fineline Cube

Follow:
14496 Articles
Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers
CompanyDrug

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Biokin's BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies
CompanyDrug

Biokin’s BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Haisco's HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation
CompanyDrug

Haisco’s HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

Boehringer Ingelheim and WHO Foundation Launch Three‑Year, USD 5 Million Collaboration to Tackle Obesity in Resource‑Limited Settings
CompanyDeals

Boehringer Ingelheim and WHO Foundation Launch Three‑Year, USD 5 Million Collaboration to Tackle Obesity in Resource‑Limited Settings

Three Oncology Assets Join CDE Pilot Programs – ICP‑B794 and Aponermin Enter "Care Program – Extension" While GH56 Advances Pediatric Development
Policy / Regulatory

Three Oncology Assets Join CDE Pilot Programs – ICP‑B794 and Aponermin Enter “Care Program – Extension” While GH56 Advances Pediatric Development

Leads Biolabs' LBL-024 Granted Orphan Drug Designation by Japan's MHLW – Anti‑PD‑L1/4‑1BB Bispecific Antibody Advances in Extrapulmonary Neuroendocrine Carcinoma
CompanyDrug

Leads Biolabs’ LBL-024 Granted Orphan Drug Designation by Japan’s MHLW – Anti‑PD‑L1/4‑1BB Bispecific Antibody Advances in Extrapulmonary Neuroendocrine Carcinoma

Evive Biotech Doses First Participant in Phase II Study of F-652 for Acute GVHD – Yifan Pharmaceutical's First‑in‑Class IL-22 Fusion Protein Advances Post‑HSCT Treatment
CompanyDrug

Evive Biotech Doses First Participant in Phase II Study of F-652 for Acute GVHD – Yifan Pharmaceutical’s First‑in‑Class IL-22 Fusion Protein Advances Post‑HSCT Treatment

Synphatec Completes Over USD 50 Million Series A to Advance CNS Pipeline – Rapid‑Acting Antidepressant SP-101 and Alzheimer's Gene Therapy SP-201 Enter Next Development Phase
CompanyDeals

Synphatec Completes Over USD 50 Million Series A to Advance CNS Pipeline – Rapid‑Acting Antidepressant SP-101 and Alzheimer’s Gene Therapy SP-201 Enter Next Development Phase

Earendil Labs Strikes Bispecific Antibody Deal with Genentech – $55 Million Upfront, Total Value Tops $1.5 Billion in Oncology
CompanyDeals

Earendil Labs Strikes Bispecific Antibody Deal with Genentech – $55 Million Upfront, Total Value Tops $1.5 Billion in Oncology

Company

Tigermed Posts 14% Revenue Growth in 2026 Interim Results – China’s No.1 Clinical CRO Sees Bookings Rebound While Fair‑Value Losses Swing Reported Profit Negative

Rainmed Medical Reports 41% Revenue Growth in 2026 Interim Results – caFFR Consumables Drive Gross Margin to 63.2% as Losses Narrow 31%
Company

Rainmed Medical Reports 41% Revenue Growth in 2026 Interim Results – caFFR Consumables Drive Gross Margin to 63.2% as Losses Narrow 31%